Document ID: chunk:federal_register_of_legislation:F2025C00194:reg:14247
Version: federal_register_of_legislation:F2025C00194
Segment Type: reg
Provision Reference: reg 14247
Character Range: 6799–8071

14247                                               Extracorporeal photopheresis for the treatment of erythrodermic stage III‑IVa T4 M0 cutaneous T‑cell lymphoma; if                                                              1,925.55
                                                        (a) the service is provided in the initial six months of treatment; and
                                                        (b) the service is delivered using an integrated, closed extracorporeal photopheresis system; and
                                                        (c) the patient is 18 years old or over; and
                                                        (d) the patient has received prior systemic treatment for this condition and experienced either disease progression or unacceptable toxicity while on this treatment; and
                                                        (e) the service is provided in combination with the use of Pharmaceutical Benefits Scheme‑subsidised methoxsalen; and
                                                        (f) the service is supervised by a specialist or consultant physician in the speciality of haematology.

                                                    Applicable once per treatment cycle (H)